Individualized Prophylaxis for Severe Hemophilia A Children

NCT ID: NCT02116855

Last Updated: 2014-04-17

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: NA
• Total Enrollment: 50 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-06-30

Brief Summary

A multi centre two year long term escalating dose tertiary prophylaxis study on the efficacy and cost saving of individualized low dose prophylaxis regimens for boys with severe hemophilia A in China staring with a low dose regimen in step I, an escalated low dose regimen in step II and a tailored dose regimen based on individual PK profiles in step III. The dose escalation criteria are adjusted according to patterns and frequencies of joint bleeding and assessed in each subject every 3 months. Efficacy of the 3 different dose regimens are measured by the Annualized Joint Bleeding rate (AJBR) as a primary end point and the Hemophilia Joint Health Score (HJHS ) and QoL scores (CHO-KLAT and PedsQoL) , image studies of target joints by Ultrasound, X-ray and MRI examinations, consumption of factor VIII and inhibitor rates as secondary end points.

Conditions

Hemophilia

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Study Groups

tertiary prophylaxis prophy on Hemophilia A patiets

A multi centre 2 year long term tertiary prophylaxis study designed with a three step escalating dose protocol adjusted by individual joint bleeding patterns/frequencies to study the effect and cost saving of 3 low dose /cost prophylaxis regimens in boys with severe hemophilia A and arthropathy in China. Each patient will start treatment with a low dose regimen in step I and be assessed every 3 months according to the escalating criteria.

Group Type: EXPERIMENTAL

according to the efficacy of AJBRs

Intervention Type: OTHER

Interventions

according to the efficacy of AJBRs

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

1. Severe hemophilia A with FVIII <1 %

2. Age from 6 to 10 years

3. Patients with more than 50 exposure day (ED)

4. Patients with one or more target joints (a target joint is defined as a joint with 3 or more bleeds in a consecutive 3 months) or disease joints (defined as presence of visible joint swelling and /or limitation of movements and/or joint deformities in the absent of an acute joint bleed )

5. on-demand treatment more than 12months before the study

Exclusion Criteria

1. A history of FVIII inhibitor (titer greater than 0.6 BU) and detectable FVIII inhibitor at screening (titer greater than 0.6 BU)

2. Chronic renal failure (serum creatinine greater than 2.0 mg /dL)

3. Chronic Liver disease (ALT greater than 200 U/L))

4. Patients with clinically documented immunodeficiencies

5. Patients anticipated to require Major surgery

6. Patients with competing high risks such as symptomatic HIV infection, Juvenile rheumatoid arthritis, metabolic bone diseases, or other diseases known to mimic or cause joint diseases

7. Patients live too far from the comprehensive care centre at BCH and had demonstrated previous non compliance to therapies or clinical studies

• Minimum Eligible Age: 6 Years
• Maximum Eligible Age: 10 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: No

Sponsors

Beijing Children's Hospital

OTHER

Sponsor Role: lead

Responsible Party

Runhui WU

Deputy Director of Hematology-Oncology Center

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

hui R Wu, MD

Role: STUDY_CHAIR

Beijing Children's Hospital

Central Contacts

Hui R Wu, MD

Role: CONTACT

runhuiwu@hotmail.com

8613911383480

Other Identifiers

BCH-20140415

Identifier Type: -

Identifier Source: org_study_id